These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 26070553)

  • 1. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccines for the treatment of glioblastoma.
    Swartz AM; Batich KA; Fecci PE; Sampson JH
    J Neurooncol; 2015 Jul; 123(3):433-40. PubMed ID: 25491947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoengineering in glioblastoma imaging and therapy.
    Zanganeh S; Georgala P; Corbo C; Arabi L; Ho JQ; Javdani N; Sepand MR; Cruickshank K; Campesato LF; Weng CH; Hemayat S; Andreou C; Alvim R; Hutter G; Rafat M; Mahmoudi M
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1575. PubMed ID: 31407522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
    Yang J; Shi Z; Liu R; Wu Y; Zhang X
    Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoformulations for glioblastoma multiforme: a new hope for treatment.
    Ortiz R; Cabeza L; Perazzoli G; Jimenez-Lopez J; García-Pinel B; Melguizo C; Prados J
    Future Med Chem; 2019 Sep; 11(18):2459-2480. PubMed ID: 31544490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation for glioblastoma.
    Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
    Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.